국소 분절 사구체 경화증(FSGS) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Focal Segmental Glomerulosclerosis Market - Scope of Report

TMR's report on the global focal segmental glomerulosclerosis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global focal segmental glomerulosclerosis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global focal segmental glomerulosclerosis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the focal segmental glomerulosclerosis market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global focal segmental glomerulosclerosis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global focal segmental glomerulosclerosis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global focal segmental glomerulosclerosis market.

The report delves into the competitive landscape of the global focal segmental glomerulosclerosis market. Key players operating in the global focal segmental glomerulosclerosis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global focal segmental glomerulosclerosis market profiled in this report.

Key Questions Answered in Global focal segmental glomerulosclerosis Market Report:

• What is the sales/revenue generated by focal segmental glomerulosclerosis across all regions during the forecast period?
• What are the opportunities in the global focal segmental glomerulosclerosis market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Focal Segmental Glomerulosclerosis Market - Research Objectives and Research Approach

The comprehensive report on the global focal segmental glomerulosclerosis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global focal segmental glomerulosclerosis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global focal segmental glomerulosclerosis market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Focal Segmental Glomerulosclerosis Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Disease Type Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Disease Type/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Disease Type, 2017-2031
  • 6.3.1. Primary Focal Segmental Glomerulosclerosis
  • 6.3.2. Secondary Focal Segmental Glomerulosclerosis
• 6.4. Market Attractiveness Analysis, by Disease Type

7. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Disease Management, 2017-2031
  • 7.3.1. Diagnosis
    • 7.3.1.1. Kidney Biopsy
    • 7.3.1.2. Creatinine Test
    • 7.3.1.3. Others
  • 7.3.2. Treatment
    • 7.3.2.1. Drug Therapy
    • 7.3.2.2. Dialysis
    • 7.3.2.3. Kidney Transplant
• 7.4. Market Attractiveness Analysis, by Disease Management

8. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region, 2017-2031
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

• 9.1. Introduction
• 9.2. Key Findings
• 9.3. Market Value Forecast, by Disease Type, 2017-2031
  • 9.3.1. Primary Focal Segmental Glomerulosclerosis
  • 9.3.2. Secondary Focal Segmental Glomerulosclerosis
• 9.4. Market Value Forecast, by Disease Management, 2017-2031
  • 9.4.1. Diagnosis
    • 9.4.1.1. Kidney Biopsy
    • 9.4.1.2. Creatinine Test
    • 9.4.1.3. Others
  • 9.4.2. Treatment
    • 9.4.2.1. Drug Therapy
    • 9.4.2.2. Dialysis
    • 9.4.2.3. Kidney Transplant
• 9.5. Market Value Forecast, by Country, 2017-2031
  • 9.5.1. U.S.
  • 9.5.2. Canada
• 9.6. Market Attractiveness Analysis
  • 9.6.1. By Disease Type
  • 9.6.2. By Disease Management
  • 9.6.3. By Country

10. Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Disease Type, 2017-2031
  • 10.3.1. Primary Focal Segmental Glomerulosclerosis
  • 10.3.2. Secondary Focal Segmental Glomerulosclerosis
• 10.4. Market Value Forecast, by Disease Management, 2017-2031
  • 10.4.1. Diagnosis
    • 10.4.1.1. Kidney Biopsy
    • 10.4.1.2. Creatinine Test
    • 10.4.1.3. Others
  • 10.4.2. Treatment
    • 10.4.2.1. Drug Therapy
    • 10.4.2.2. Dialysis
    • 10.4.2.3. Kidney Transplant
• 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.5.1. Germany
  • 10.5.2. U.K.
  • 10.5.3. France
  • 10.5.4. Italy
  • 10.5.5. Spain
  • 10.5.6. Rest of Europe
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Disease Type
  • 10.6.2. By Disease Management
  • 10.6.3. By Country/Sub-region

11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Disease Type, 2017-2031
  • 11.3.1. Primary Focal Segmental Glomerulosclerosis
  • 11.3.2. Secondary Focal Segmental Glomerulosclerosis
• 11.4. Market Value Forecast, by Disease Management, 2017-2031
  • 11.4.1. Diagnosis
    • 11.4.1.1. Kidney Biopsy
    • 11.4.1.2. Creatinine Test
    • 11.4.1.3. Others
  • 11.4.2. Treatment
    • 11.4.2.1. Drug Therapy
    • 11.4.2.2. Dialysis
    • 11.4.2.3. Kidney Transplant
• 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.5.1. China
  • 11.5.2. Japan
  • 11.5.3. India
  • 11.5.4. Australia & New Zealand
  • 11.5.5. Rest of Asia Pacific
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Disease Type
  • 11.6.2. By Disease Management
  • 11.6.3. By Country/Sub-region

12. Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Disease Type, 2017-2031
  • 12.3.1. Primary Focal Segmental Glomerulosclerosis
  • 12.3.2. Secondary Focal Segmental Glomerulosclerosis
• 12.4. Market Value Forecast, by Disease Management, 2017-2031
  • 12.4.1. Diagnosis
    • 12.4.1.1. Kidney Biopsy
    • 12.4.1.2. Creatinine Test
    • 12.4.1.3. Others
  • 12.4.2. Treatment
    • 12.4.2.1. Drug Therapy
    • 12.4.2.2. Dialysis
    • 12.4.2.3. Kidney Transplant
• 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Disease Type
  • 12.6.2. By Disease Management
  • 12.6.3. By Country/Sub-region

13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Disease Type, 2017-2031
  • 13.3.1. Primary Focal Segmental Glomerulosclerosis
  • 13.3.2. Secondary Focal Segmental Glomerulosclerosis
• 13.4. Market Value Forecast, by Disease Management, 2017-2031
  • 13.4.1. Diagnosis
    • 13.4.1.1. Kidney Biopsy
    • 13.4.1.2. Creatinine Test
    • 13.4.1.3. Others
  • 13.4.2. Treatment
    • 13.4.2.1. Drug Therapy
    • 13.4.2.2. Dialysis
    • 13.4.2.3. Kidney Transplant
• 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.5.1. GCC Countries
  • 13.5.2. South Africa
  • 13.5.3. Rest of Middle East & Africa
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Disease Type
  • 13.6.2. By Disease Management
  • 13.6.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 14.2. Market Share Analysis, by Company (2022)
• 14.3. Company Profiles
  • 14.3.1. Variant Pharmaceuticals, Inc.
    • 14.3.1.1. Company Overview
    • 14.3.1.2. Disease Type Portfolio
    • 14.3.1.3. SWOT Analysis
    • 14.3.1.4. Financial Overview
    • 14.3.1.5. Strategic Overview
  • 14.3.2. ChemoCentryx, Inc.
    • 14.3.2.1. Company Overview
    • 14.3.2.2. Disease Type Portfolio
    • 14.3.2.3. SWOT Analysis
    • 14.3.2.4. Financial Overview
    • 14.3.2.5. Strategic Overview
  • 14.3.3. Travere Therapeutics
    • 14.3.3.1. Company Overview
    • 14.3.3.2. Disease Type Portfolio
    • 14.3.3.3. SWOT Analysis
    • 14.3.3.4. Financial Overview
    • 14.3.3.5. Strategic Overview
  • 14.3.4. AbbVie, Inc.
    • 14.3.4.1. Company Overview
    • 14.3.4.2. Disease Type Portfolio
    • 14.3.4.3. SWOT Analysis
    • 14.3.4.4. Financial Overview
    • 14.3.4.5. Strategic Overview
  • 14.3.5. Novartis AG
    • 14.3.5.1. Company Overview
    • 14.3.5.2. Disease Type Portfolio
    • 14.3.5.3. SWOT Analysis
    • 14.3.5.4. Financial Overview
    • 14.3.5.5. Strategic Overview
  • 14.3.6. Pfizer, Inc.
    • 14.3.6.1. Company Overview
    • 14.3.6.2. Disease Type Portfolio
    • 14.3.6.3. SWOT Analysis
    • 14.3.6.4. Financial Overview
    • 14.3.6.5. Strategic Overview
  • 14.3.7. AstraZeneca plc.
    • 14.3.7.1. Company Overview
    • 14.3.7.2. Disease Type Portfolio
    • 14.3.7.3. SWOT Analysis
    • 14.3.7.4. Financial Overview
    • 14.3.7.5. Strategic Overview
  • 14.3.8. Sanofi S.A.
    • 14.3.8.1. Company Overview
    • 14.3.8.2. Disease Type Portfolio
    • 14.3.8.3. SWOT Analysis
    • 14.3.8.4. Financial Overview
    • 14.3.8.5. Strategic Overview
  • 14.3.9. GlaxoSmithKline plc.
    • 14.3.9.1. Company Overview
    • 14.3.9.2. Disease Type Portfolio
    • 14.3.9.3. SWOT Analysis
    • 14.3.9.4. Financial Overview
    • 14.3.9.5. Strategic Overview
  • 14.3.10. Teva Pharmaceutical Industries Ltd.
    • 14.3.10.1. Company Overview
    • 14.3.10.2. Disease Type Portfolio
    • 14.3.10.3. SWOT Analysis
    • 14.3.10.4. Financial Overview
    • 14.3.10.5. Strategic Overview